Last updated: July 31, 2026
Enalaprilat is a mature, hospital-focused generic ACE inhibitor sold primarily as an intravenous injection. Its commercial value is limited by narrow use, oral ACE-inhibitor substitution, low unit prices, and competition from other injectable antihypertensives. The product has no meaningful remaining branded exclusivity or biosimilar protection. Financial performance is driven by hospital contract awards, manufacturing continuity, shortages, and supply concentration rather than patent-based pricing power.
What is enalaprilat and how is it used?
Enalaprilat is the active intravenous metabolite of enalapril. It inhibits angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone secretion. The injectable product is supplied at 1.25 mg/mL and is used for the treatment of hypertension when oral therapy is impractical or inappropriate.[1]
| Attribute |
Enalaprilat |
| Active ingredient |
Enalaprilat |
| Drug class |
ACE inhibitor |
| Route |
Intravenous |
| Common strength |
1.25 mg/mL |
| Primary FDA-labeled use |
Hypertension |
| Typical setting |
Hospital and inpatient care |
| Original branded product |
Vasotec Injection |
| Current commercial model |
Generic injectable |
| Biosimilar relevance |
None |
| Patent-driven pricing power |
Minimal |
The product is not a routine outpatient prescription medicine. Its use is concentrated in inpatient settings, emergency departments, intensive-care units, and other situations in which a patient cannot take oral medication. That limits total volume compared with oral enalapril, lisinopril, losartan, or newer cardiovascular drugs.
What is the FDA regulatory status of enalaprilat?
Enalaprilat injection is an FDA-approved prescription drug marketed through abbreviated new drug applications and legacy branded approvals. The FDA label identifies intravenous enalaprilat for hypertension and describes dosing adjustments based on renal function and prior diuretic use.[1]
The product has several clinical limitations:
- It has a relatively slow and prolonged antihypertensive effect for a titratable hospital drug.
- It can cause hypotension, particularly in volume-depleted patients.
- It requires renal-function monitoring.
- It is contraindicated with a history of angioedema related to ACE-inhibitor therapy.
- It carries fetal toxicity risks and is contraindicated during pregnancy.[1]
These characteristics reduce its role in rapidly controlled hypertension, where hospitals may prefer titratable intravenous agents such as nicardipine, clevidipine, labetalol, or esmolol.
How does enalaprilat compare with oral enalapril?
Oral enalapril is widely used for chronic hypertension and heart failure. Enalaprilat is used when oral administration is not feasible. The two products are pharmacologically related but occupy different commercial channels.
| Factor |
Enalaprilat injection |
Oral enalapril |
| Administration |
Intravenous |
Oral |
| Main market |
Hospitals |
Retail and mail-order pharmacies |
| Patient duration |
Short-term inpatient use |
Chronic treatment |
| Price sensitivity |
Hospital contract pricing |
Generic pharmacy pricing |
| Substitution risk |
High from other IV agents |
High from multiple oral ACE inhibitors and ARBs |
| Revenue scale |
Small |
Larger generic volume |
| Patent value |
None of practical significance |
None of practical significance |
The injectable product cannot be treated as a direct substitute for oral enalapril in patients who can swallow and absorb oral medication. Its market depends on a narrow clinical requirement rather than broad chronic cardiovascular demand.
When does enalaprilat lose exclusivity?
Enalaprilat has already lost meaningful market exclusivity. The original Vasotec franchise dates from the 1980s, and the product is now sold as a mature generic injectable. FDA Orange Book and Drugs@FDA records do not indicate an active branded exclusivity period that would prevent approved generic competition.[2,3]
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No active commercial relevance |
| Branded patent exclusivity |
Expired |
| Generic competition |
Permitted |
| Biosimilar exclusivity |
Not applicable |
No credible commercial thesis depends on restoring enalaprilat exclusivity through a conventional patent strategy. Any new protection would need to attach to a genuinely novel formulation, delivery system, manufacturing process, or clinical use. Such protection would face obviousness, written-description, enablement, and freedom-to-operate challenges because the active ingredient and basic injectable use are established.
What patents protect enalaprilat?
The commercially relevant patent estate for standard enalaprilat injection is effectively exhausted. The original enalapril and enalaprilat chemistry and pharmaceutical-use rights are historical assets rather than current barriers to generic entry.
The principal patent-related conclusions are:
- Standard enalaprilat injection does not depend on an active composition-of-matter patent.
- Generic manufacturers can compete through abbreviated new drug applications.
- No patent-based premium supports the standard 1.25 mg/mL injectable product.
- Any remaining patents associated with alternative formulations or processes would need to be evaluated separately from the conventional product.
- Patent risk is materially lower than manufacturing, regulatory, and contracting risk.
A patent-number inventory is not economically meaningful without a defined jurisdiction, dosage form, formulation, or product applicant. The relevant commercial product is the established injectable formulation listed in FDA-approved labeling, not a protected novel-delivery platform.
What is the Orange Book status of enalaprilat?
The Orange Book framework is relevant because enalaprilat injection is an approved small-molecule drug and generic applicants may rely on an abbreviated application pathway. The product has no biosimilar pathway because biosimilars apply to biological products, not conventional small-molecule ACE inhibitors.[2]
For market participants, the practical Orange Book position is:
- Generic approval is available through an ANDA route.
- No current branded exclusivity blocks generic substitution.
- Paragraph IV litigation is not a central market issue.
- The product is exposed to multiple approved or approvable generic suppliers.
- Labeling and pharmaceutical-equivalence requirements matter more than patent certifications.
Which companies are challenging or supplying enalaprilat?
Enalaprilat is supplied through the generic injectable market rather than through a branded competitive campaign. Depending on the procurement period and product availability, hospital buyers may encounter manufacturers such as Hikma Pharmaceuticals, Fresenius Kabi, and other FDA-approved generic injectable suppliers. Product availability can vary because manufacturers may discontinue presentations, change national distribution, or experience temporary shortages.
The competitive landscape is shaped by:
- FDA approval status
- Current manufacturing capacity
- Injectable-facility reliability
- Hospital group-purchasing contracts
- Wholesale-distribution access
- Availability of the specific vial or ampule presentation
- Sterile manufacturing compliance
- Ability to maintain supply during shortages
Supplier identity should be verified against the current FDA product listing and DailyMed label because generic ownership, marketing status, and National Drug Code availability can change.[1,3]
Are there Paragraph IV challenges or enalaprilat patent lawsuits?
No major current Paragraph IV litigation is central to the standard enalaprilat injection market. The reason is structural: the product is a mature generic with no commercially important unexpired branded patent barrier.
Litigation exposure is more likely to arise from:
- Manufacturing defects
- Current good manufacturing practice violations
- Product liability claims
- Distribution and contracting disputes
- Drug-shortage allocation
- Antitrust issues involving generic supply
- Patent disputes over a newly developed formulation or delivery device
A generic entrant would usually face a regulatory and commercial execution problem rather than a patent-litigation problem. The absence of active patent litigation does not eliminate launch risk, because sterile injectable products require facility capacity, validated processes, approved specifications, and reliable supply.
What formulations are protected by enalaprilat patents?
The standard formulation is an aqueous intravenous injection. Its commercial differentiation is limited. Potentially protectable areas could include:
- Reduced-sodium formulations
- Improved stability packages
- Premixed ready-to-administer bags
- Novel vial or syringe presentations
- Preservative systems
- Extended-storage formulations
- Combination products
- Alternative delivery systems
These concepts would not automatically create enforceable market protection. A formulation patent would need to demonstrate a non-obvious technical effect, such as improved stability, reduced degradation, enhanced compatibility, or a measurable clinical or manufacturing advantage.
The market opportunity for such protection is limited because hospitals often prioritize low acquisition cost and operational convenience. A ready-to-administer presentation could command a premium if it reduces pharmacy compounding or nursing time, but the premium would depend on procurement policy and demonstrated workflow savings.
How strong is the enalaprilat patent estate?
The patent estate for ordinary enalaprilat injection is weak from a commercial-protection perspective. Its strength is best characterized as follows:
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core method-of-use protection |
Expired or commercially irrelevant |
| Standard injection formulation |
Mature and vulnerable to generic competition |
| Active Orange Book barrier |
None of practical significance |
| Paragraph IV risk |
Low |
| Manufacturing know-how value |
Moderate |
| Sterile-facility barrier |
High relative to patent risk |
| New formulation opportunity |
Possible but narrow |
| Litigation leverage |
Low |
Manufacturing know-how has greater economic importance than legacy patents. Sterile injectable production is difficult to scale, and a supplier may retain share because it can produce consistently even when the product itself is not differentiated.
What is the enalaprilat market size and revenue exposure?
Public companies generally do not disclose standalone enalaprilat revenue. The product is usually included within broader generic injectable, hospital products, or cardiovascular portfolios. As a result, precise market size, product-level sales, gross margin, and market-share estimates are not reliably available from public filings.
The financial profile is nevertheless clear:
- Unit pricing is generic and subject to hospital contracting.
- Total addressable volume is small compared with oral antihypertensives.
- Revenue is concentrated in institutional purchasing.
- Margin can be affected by sterile-manufacturing costs and low production runs.
- Shortages can create temporary pricing increases but can also cause lost sales and regulatory scrutiny.
- A manufacturer with a reliable supply position may earn better economics than a late entrant despite no patent advantage.
For a generic manufacturer, enalaprilat is more likely to be a portfolio-completion product than a major growth driver. Its value may come from retaining hospital formulary access, filling an injectable-product gap, or using existing sterile capacity rather than generating substantial standalone revenue.
What financial trajectory should investors expect?
The base-case financial trajectory is flat to declining in nominal terms, with intermittent volatility.
| Period |
Expected commercial pattern |
| Historical branded period |
Higher pricing and limited competition |
| Early generic period |
Rapid price erosion and supplier expansion |
| Mature generic period |
Low prices, stable but limited demand |
| Shortage periods |
Temporary price and volume volatility |
| Long-term outlook |
Flat or declining demand with occasional supply-driven spikes |
Demand may decline over time if hospitals increasingly use oral therapy earlier, adopt more titratable intravenous agents, or reduce enalaprilat use through protocol changes. Volume can remain stable where enalaprilat is embedded in formularies or used for selected patients who cannot receive oral medication.
The strongest financial opportunity is not a conventional price increase. It is a differentiated presentation that reduces hospital labor, a reliable supply contract, or a manufacturing-cost advantage.
What generic launch risks exist for enalaprilat?
A new generic entrant would face limited patent risk but meaningful operational risk.
Regulatory and manufacturing risks
FDA approval depends on pharmaceutical equivalence, bioequivalence or applicable waiver standards, container-closure compatibility, sterility assurance, stability data, and compliance with current good manufacturing practices.[3,4]
Sterile injectable products have higher failure consequences than oral tablets. A manufacturing interruption can remove a supplier from hospital contracts and create a shortage. Facility remediation, inspection findings, particulate contamination, endotoxin failures, and container-closure problems can materially affect launch economics.
Commercial risks
A new entrant would likely encounter:
- Low reimbursement leverage
- Hospital purchasing concentration
- Contractual price competition
- Limited clinical differentiation
- Small market volume
- Dependence on wholesalers and group-purchasing organizations
- Substitution by alternative intravenous antihypertensives
A launch can be commercially rational if the manufacturer already has a sterile injectable facility and distribution infrastructure. It is less attractive as a standalone investment requiring new capacity.
How does enalaprilat compare with competing intravenous antihypertensives?
Enalaprilat competes most directly with hospital-administered intravenous agents, not with all antihypertensive drugs.
| Product |
Main advantage over enalaprilat |
Main limitation |
| Nicardipine |
Titration and predictable infusion control |
Requires infusion monitoring |
| Clevidipine |
Very rapid titration and short half-life |
Higher acquisition cost |
| Labetalol |
Broad hospital familiarity and bolus/infusion use |
Bradycardia and bronchospasm concerns |
| Hydralazine injection |
Low-cost intermittent dosing |
Less predictable response |
| Enalaprilat |
ACE-inhibitor mechanism and intermittent IV dosing |
Slow, prolonged effect and renal/hypotension concerns |
Enalaprilat can retain a niche where clinicians specifically want ACE inhibition and oral therapy is unavailable. It is less competitive where rapid titration is the primary clinical objective.
What manufacturing and intellectual-property barriers affect the market?
The principal barrier is sterile injectable execution. Manufacturers must maintain validated aseptic processing, testing, packaging, and supply-chain controls. Enalaprilat’s low price makes manufacturing efficiency important because fixed quality costs are spread over a relatively small product base.
Geographic protection is limited. FDA approval supports U.S. marketing, while Europe and other jurisdictions require separate regulatory approvals and may have different supplier structures. Legacy patents are unlikely to create meaningful geographic exclusivity. Commercial barriers instead arise from:
- National regulatory approvals
- Local procurement rules
- Import and serialization requirements
- Hospital tender systems
- Regional manufacturing capacity
- Distribution agreements
What is the outlook for enalaprilat?
Enalaprilat should be viewed as a stable but low-growth generic injectable. Its strategic value lies in supply reliability, hospital formulary participation, and portfolio economics. Patent-driven upside is negligible, biosimilar risk is irrelevant, and standalone revenue growth is unlikely without a differentiated presentation or supply disruption affecting competitors.
Key Takeaways
- Enalaprilat is a mature intravenous generic ACE inhibitor used mainly in hospitals.
- Standard enalaprilat injection has no meaningful remaining branded exclusivity.
- The product has no biosimilar pathway because it is a small-molecule drug.
- Paragraph IV and patent-litigation risk are low for the conventional formulation.
- Hospital contracting, sterile manufacturing, and supply continuity determine market performance.
- Public companies generally do not report standalone enalaprilat revenue.
- The base-case financial trajectory is stable to declining, with temporary volatility during shortages.
- A new entrant would need manufacturing or presentation advantages, not patent leverage, to build share.
Frequently Asked Questions
Is enalaprilat still commercially available in the United States?
Yes. Enalaprilat injection has been marketed as an approved generic product, although specific suppliers, presentations, and availability can change.
Is enalaprilat a branded or generic drug?
It is primarily a generic drug. The historical branded product was Vasotec Injection, originally associated with Merck.
Can enalaprilat be substituted for lisinopril?
No. Both are ACE inhibitors, but enalaprilat is administered intravenously while lisinopril is generally administered orally. Clinical substitution requires physician judgment and consideration of route, dose, renal function, and patient condition.
Does enalaprilat have an orphan-drug opportunity?
No established orphan-drug opportunity is associated with standard enalaprilat injection. Its labeled use is hypertension, a common condition.
Could a premixed enalaprilat product obtain new patent protection?
Potentially, but any patent would need to protect a novel and non-obvious formulation, container, stability profile, or delivery system. A simple repackaging of established enalaprilat injection would face substantial patentability and commercial challenges.
References
- DailyMed. (n.d.). Enalaprilat injection prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210-211.
